Virax Holdings Limited, Kew, VIC

Prescient Therapeutics is an Australian based, clinical stage oncology company committed to developing and commercialising novel products that have great potential to improve standard cancer treatments around the world. Listed on the Australian Stock Exchange (ASX), the company holds an exclusive worldwide license to the highly promising cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. GGTI-2418 is expected to enter Phase 1b/2 clinical trials in breast cancer and myeloma in early 2015. In addition, Prescient has recently acquired US oncology company AKTivate Therapeutics and its novel TCN-P cancer drug - a second and equally promising novel drug candidate. TCN-P is currently in two active clinical trials - a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defense and National Cancer Institute. Prescient’s portfolio also includes a third platform - the Co-X-Gene technology. The Company has granted a license to major French biotechnology company Transgene for access to this Co-X-Gene technology for use in two of Transgene’s immunotherapeutic products.